183 related articles for article (PubMed ID: 17496901)
1. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas.
Hernando E; Charytonowicz E; Dudas ME; Menendez S; Matushansky I; Mills J; Socci ND; Behrendt N; Ma L; Maki RG; Pandolfi PP; Cordon-Cardo C
Nat Med; 2007 Jun; 13(6):748-53. PubMed ID: 17496901
[TBL] [Abstract][Full Text] [Related]
2. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma.
Marsh J; Mukherjee P; Seyfried TN
Clin Cancer Res; 2008 Dec; 14(23):7751-62. PubMed ID: 19047102
[TBL] [Abstract][Full Text] [Related]
3. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.
Yao D; Alexander CL; Quinn JA; Porter MJ; Wu H; Greenhalgh DA
Cancer Res; 2006 Feb; 66(3):1302-12. PubMed ID: 16452183
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
Porta C; Figlin RA
J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
[TBL] [Abstract][Full Text] [Related]
7. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.
Dan HC; Adli M; Baldwin AS
Cancer Res; 2007 Jul; 67(13):6263-9. PubMed ID: 17616684
[TBL] [Abstract][Full Text] [Related]
8. Renal activity of Akt kinase in obese Zucker rats.
Zdychová J; Kazdová L; Pelikanová T; Lindsley JN; Anderson S; Komers R
Exp Biol Med (Maywood); 2008 Oct; 233(10):1231-41. PubMed ID: 18641049
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway.
Kimura R; Okouchi M; Fujioka H; Ichiyanagi A; Ryuge F; Mizuno T; Imaeda K; Okayama N; Kamiya Y; Asai K; Joh T
Neuroscience; 2009 Sep; 162(4):1212-9. PubMed ID: 19463904
[TBL] [Abstract][Full Text] [Related]
10. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
11. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
[TBL] [Abstract][Full Text] [Related]
12. Role of PTEN/PI3K pathway in endothelial cells.
Suzuki A; Hamada K; Sasaki T; Mak TW; Nakano T
Biochem Soc Trans; 2007 Apr; 35(Pt 2):172-6. PubMed ID: 17371230
[TBL] [Abstract][Full Text] [Related]
13. Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice.
Strizzi L; Bianco C; Hirota M; Watanabe K; Mancino M; Hamada S; Raafat A; Lawson S; Ebert AD; D'Antonio A; Losito S; Normanno N; Salomon DS
J Pathol; 2007 Jan; 211(1):36-44. PubMed ID: 17072826
[TBL] [Abstract][Full Text] [Related]
14. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
Setsu N; Yamamoto H; Kohashi K; Endo M; Matsuda S; Yokoyama R; Nishiyama K; Iwamoto Y; Dobashi Y; Oda Y
Cancer; 2012 Mar; 118(6):1637-48. PubMed ID: 21837670
[TBL] [Abstract][Full Text] [Related]
15. From PTEN loss of expression to RICTOR role in smooth muscle differentiation: complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas.
Gibault L; Ferreira C; Pérot G; Audebourg A; Chibon F; Bonnin S; Lagarde P; Vacher-Lavenu MC; Terrier P; Coindre JM; Aurias A
Mod Pathol; 2012 Feb; 25(2):197-211. PubMed ID: 22080063
[TBL] [Abstract][Full Text] [Related]
16. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans.
Carrasco DR; Fenton T; Sukhdeo K; Protopopova M; Enos M; You MJ; Di Vizio D; Nogueira C; Stommel J; Pinkus GS; Fletcher C; Hornick JL; Cavenee WK; Furnari FB; Depinho RA
Cancer Cell; 2006 May; 9(5):379-90. PubMed ID: 16697958
[TBL] [Abstract][Full Text] [Related]
17. Lifelong accumulation of bone in mice lacking Pten in osteoblasts.
Liu X; Bruxvoort KJ; Zylstra CR; Liu J; Cichowski R; Faugere MC; Bouxsein ML; Wan C; Williams BO; Clemens TL
Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2259-64. PubMed ID: 17287359
[TBL] [Abstract][Full Text] [Related]
18. Akt signaling and growth of the heart.
Walsh K
Circulation; 2006 May; 113(17):2032-4. PubMed ID: 16651482
[No Abstract] [Full Text] [Related]
19. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.
Knowles MA; Platt FM; Ross RL; Hurst CD
Cancer Metastasis Rev; 2009 Dec; 28(3-4):305-16. PubMed ID: 20013032
[TBL] [Abstract][Full Text] [Related]
20. Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.
Guijarro MV; Dahiya S; Danielson LS; Segura MF; Vales-Lara FM; Menendez S; Popiolek D; Mittal K; Wei JJ; Zavadil J; Cordon-Cardo C; Pandolfi PP; Hernando E
Am J Pathol; 2013 Jun; 182(6):2015-27. PubMed ID: 23708211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
